- Translational Research
- Single-cell genomics/transcriptomics/proteomics
- Next-generation (DNA/Exome/whole genome/RNA) sequencing, SNP arrays and Microarrays
- Functional genomics/ Cell and Molecular Biology
- Bioinformatics and Computational Biology
- Population Genetics
Dr. Mitra's current research focuses on identifying the genomic and pharmacogenomic factors governing the wide heterogeneity in human diseases including multiple myeloma, AML and solid tumors that influence susceptibility, disease progression, clinical aggressiveness, drug sensitivity and eventual treatment outcomes.
Research: Focuses on using multi-omics approaches to investigate inter-tumor (between-tumor) and intra-tumor (within-tumor or subclonal) heterogeneity in tumor progression, clinical aggressiveness, drug response, and eventual treatment outcomes in human cancers, particularly multiple myeloma. Current research involves integrating genomics (exome sequencing), transcriptomics (RNA sequencing), single-cell -omics, in vitro drug response modeling, and functional genomics (CRISPR, molecular genetics) with translational bioinformatics to generate pharmacogenomic signatures as predictive markers of drug sensitivity/resistance. Established a computational algorithm-based pipeline to predict, characterize and functionally validate novel combination therapies against relapsed/refractory cancers resistant to standard-of-care drugs. Also directing the Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx)